mPRα mediates P4/Org OD02‐0 to improve the sensitivity of lung adenocarcinoma to EGFR‐TKIs via the EGFR‐SRC‐ERK1/2 pathway

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Progesterone suppresses triple-negative breast cancer growth and metastasis to the brain via membrane progesterone receptor α

(2017) Li Zhou et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Progesterone Receptor Signaling Mechanisms

(2016) Sandra L. Grimm et al.   JOURNAL OF MOLECULAR BIOLOGY

Interplay of nuclear receptors (ER, PR, and GR) and their steroid hormones in MCF-7 cells

(2016) Shubha M. Hegde et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance

(2016) Yasuaki Kabe et al.   Nature Communications

Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer?

(2016) Fang Shen et al.   Oncotarget

May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer?

(2015) Ying Zhang et al.   GYNECOLOGICAL ENDOCRINOLOGY

Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability

(2015) D-W Wu et al.   ONCOGENE

The prognostic role of progesterone receptor expression in non-small cell lung cancer patients: Gender-related impacts and correlation with disease-specific survival

(2015) Kaja Skjefstad et al.   STEROIDS

Progesterone Receptor Membrane Component-1 (PGRMC1) and PGRMC-2 Interact to Suppress Entry into the Cell Cycle in Spontaneously Immortalized Rat Granulosa Cells1

(2014) John J. Peluso et al.   BIOLOGY OF REPRODUCTION

Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities

(2014) J. Munoz et al.   CANCER AND METASTASIS REVIEWS

Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer

(2014) T. Yoshida et al.   CLINICAL CANCER RESEARCH

Enhancement of Cell Surface Expression and Receptor Functions of Membrane Progestin Receptor α (mPRα) by Progesterone Receptor Membrane Component 1 (PGRMC1): Evidence for a Role of PGRMC1 as an Adaptor Protein for Steroid Receptors

(2014) Peter Thomas et al.   ENDOCRINOLOGY

Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer

(2014) Nobuaki Ochi et al.   EXPERIMENTAL CELL RESEARCH

Membrane progestin receptor alpha mediates progestin-induced sperm hypermotility and increased fertilization success in southern flounder (Paralichthys lethostigma)

(2014) Wenxian Tan et al.   GENERAL AND COMPARATIVE ENDOCRINOLOGY

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells

(2013) Caroline Diep et al.   CELL CYCLE

The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer

(2013) Akin Atmaca et al.   INTERNATIONAL JOURNAL OF CANCER

Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1

(2013) Jing Zhou et al.   MATURITAS

Progesterone inhibits the migration and invasion of A549 lung cancer cells through membrane progesterone receptor α-mediated mechanisms

(2013) MINGXUAN XIE et al.   ONCOLOGY REPORTS

Biological Characteristics and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Efficacy of EGFR Mutation and its Subtypes in Lung Adenocarcinoma

(2013) Rong-li Lu et al.   PATHOLOGY & ONCOLOGY RESEARCH

Tracking progesterone receptor-mediated actions in breast cancer

(2013) Todd P. Knutson et al.   PHARMACOLOGY & THERAPEUTICS

The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

(2012) Y. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Membrane Progesterone Receptor Alpha as a Potential Prognostic Biomarker for Breast Cancer Survival: A Retrospective Study

(2012) Mingxuan Xie et al.   PLoS One

Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib

(2011) Hua Cheng et al.   Journal of Hematology & Oncology

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

The biology of progesterone receptor in the normal mammary gland and in breast cancer

(2011) Alison E. Obr et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor-Activating Mutations

(2010) C. Yamamoto et al.   CANCER RESEARCH

Pgrmc1 (Progesterone Receptor Membrane Component 1) Associates with Epidermal Growth Factor Receptor and Regulates Erlotinib Sensitivity

(2010) Ikhlas S. Ahmed et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison between steroid binding to membrane progesterone receptor α (mPRα) and to nuclear progesterone receptor: Correlation with physicochemical properties assessed by comparative molecular field analysis and identification of mPRα-specific agonists

(2010) Jan Kelder et al.   STEROIDS

Characteristics of membrane progestin receptor alpha (mPRα) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions

(2008) Peter Thomas   FRONTIERS IN NEUROENDOCRINOLOGY